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The SARS-CoV-2 is a highly infective and transmittable and
ever since it has spread worldwide quickly and became a global
public health challenge.1,2 Right now, due to lack of a vaccine
or specific antiviral treatment for human and animal corona-
viruses (CoVs), urgent identification of drug treatment for the
response to the COVID-19 outbreak is the utmost require-
ment.3 Effective antiviral therapy is important to tackle the
COVID-19 pandemic. Up to date, several antivirals, previously
developed or used as treatments for SARS (Severe Acute
Respiratory Syndrome), MERS (Middle East Respiratory Syn-
drome), human immunodeficiency virus (HIV), and malaria,
have been investigated against COVID-19 and some have
moved into clinical trials conducted around the globe.4 Some
of them have been achieved promising results so far.5 At least
23 studies of remdesivir are presently recorded on various trial
registers, proposing to study 23,500 patients, but fewer than
a quarter are double-blind, and some are uncontrolled observa-
tional studies.6 Additional information on some of the ongoing
remdesivir clinical studies7 is presented in Table 1. Despite of
the fact, remdesivir is being considered the most effective
potential agent against COVID-19 based on preliminary
in vitro and clinical studies, it still requires an elaborative
research study combining quantitatively large direct clinical
trials and in vitro studies to approve its efficacy and safety.
This study aims to highlight the potential of remdesivir in anti-
COVID-19 research to help inform clinicians considering the
use of remdesivir.
Remdesivir, a prodrug of a nucleotide analogue that pre-
vents the action of viral RNA polymerases. The original pio-
neer of remdesivir “Gilead Sciences” developed the drug to
combat Ebola and related viruses by blocking the RNA-
dependent RNA polymerase (RdRp) of pathogens.8 During the
past outbreaks that occurred due to members of few other virus
families containing Filoviruses (Ebola) and CoVs (MERS/
SARS), the antiviral remdesivir has considered to possess
broad-spectrum activity against these viruses.9 It has also been
reported from several studies that the drug holds therapeutic
efficacy and prophylactic activity in many nonclinical
models of the above CoVs.10 A report published in the journal
of NATURE biotechnology stated that the broad-spectrum
antiviral “remdesivir has quite a high potency against all dif-
ferent CoVs and therefore it is selected as one of the prime and
suitable drug candidates to start being tested.”11 World Health
Organization (WHO) in the mid of March had launched an
international level mega trial of the 4 most auspicious treat-
ments against CoV including remdesivir on top of the list with
higher potency and efficacy. According to their study, the
SARS-CoV-2 is giving this compound a second chance to
shine. A virtual meeting held on 2nd April 2020 among mem-
bers of EMA’s (Human Medicines Committee) provided rec-
ommendations on concerned usage of remdesivir as an efficient
antiviral for COVID-19 medication.12
Recently, when there is a race to find a potent drug candi-
date, remdesivir was also tested in vitro and results have pre-
sented that it has prominent activity against SARS-CoV-2 and
chosen as a strong candidate (Table 2). In vitro remdesivir has
found effective at EC90 of 1.76 mM against COVID-19 in one
study. In this study, the antiviral efficacy of remdesivir was
evaluated against a clinical isolate of SARS-CoV-2 in vitro in
Vero E6 cells and observed to potently blocked virus infection
at a low-micromolar concentration (EC50 ¼ 0.77 mM).13
According to Agostini et al., remdesivir potently inhibits
human and zoonotic CoVs in vitro and in a SARS-CoV mouse
model. They demonstrated that remdesivir inhibits CoVs
(MERS and SARS) early after infection by interfering with
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viral RNA replication at EC50 value of 0.07 mM and 0.069 mM,
respectively.14 Moreover, Gordon et al., demonstrated that
remdesivir potently inhibits RNA viruses in cell-based assays.8
In addition, Guangdi Li & De Clercq also claimed that remde-
sivir has an appropriate potential biocontainment capability
against COVID-19.15 Likewise, an in silico model built by
sequence analysis, modeling and, docking suggested the effec-
tiveness of remdesivir as a potent drug against the newly devel-
oped COVID-19.9 Furthermore, in an animal study “rhesus
macaque model of MERS-CoV infection,” prophylactic remde-
sivir treatment prevented MERS-CoV-induced clinical disease
and lung lesions in rhesus macaques inoculated with MERS-
CoV, and strongly inhibited MERS-CoV replication in respira-
tory tissues (Table 3). Since SARS-CoV-2 is mostly related to
these CoVs, it opens the gateway and could be considered for
implementation in clinical trials against SARS-CoV-2.16
Presently, there have been successful cases of remdesivir in
treating COVID-19. The first case of COVID-19 reported in the
US was a young man in Washington. He was administered with
antiviral remdesivir upon continuous aggravation of the clin-
ical symptoms on the 6th day of admission, and began to con-
tinue intravenous (I.V) remdesivir to the patient on the
following day. On the 8th day of admission, the patient’s clinical
symptoms were improved, and the oxygen saturation increased
to 94%.17 Moreover, a study entitled “Compassionate Use of
Remdesivir for Patients with Severe COVID-19” published
by J. Grein et al., reported a total of 53 infection cases of
COVID-19 that were hospitalized in more than 20 hospitals
of several affected countries, were treated with remdesivir.
The median duration of symptoms before the initiation of
remdesivir treatment was 12 days. These patients (who had
an oxygen saturation of 94% or less while they were breathing
ambient air or who were receiving oxygen support) received
the drug between January 25 and March 7, 2020, in hospitals
around the world: 22 in Europe, 22 in the USA and, 9 in Japan.
A 10-day treatment course with 200 mg loading dose on day 1
and 100 mg daily I.V up to remaining 9 days was followed and
the overall probability of improvement in the category of
oxygen support of patients by 18 days was 68%. 23% patients
in this study experienced serious adverse events such as
multiple-organ-dysfunction syndrome, septic shock, acute
kidney injury, and hypotension.18
Conferring to the Centers for Disease Control and Preven-
tion (CDC), until March 2020, one investigational agent
(remdesivir) was in use in the USA.4 Recently, an emergency
approval has granted by the U.S. Food and Drug Administra-
tion (USFDA) to use remdesivir against COVID-19 in more
hospitals around the United States,21 making it the first autho-
rized therapy for the virus. USFDA’s approval was based on
trial results which revealed that the drug reduced the recovery
time to 5 days from 10 days for moderate patients (who have
evidence of lower respiratory disease by clinical assessment or
imaging and a saturation of oxygen (SpO2)  94% on room air
at sea level). Similarly, Japan also approved remdesivir for the
treatment of severe COVID-19 patients, under an exceptional
approval pathway based on clinical data from the U.S. National
Table 1. Ongoing Remdesivir Clinical Studies.
Ongoing remdesivir clinical studies against COVID-19
Type of study Study phase Recruitment status Estimated primary completion date Identifier
– Observational – – Recruiting – October 30, 2020 – NCT04570982
– Interventional – Early Phase 1 – Recruiting – November 30, 2020 – NCT04560231
– Interventional – Phase 3 – Recruiting – December 1, 2020 – NCT04409262
– Interventional – Phase 3 – Recruiting – December 2020 – NCT04501952
– Interventional – Phase 2 Phase 3 – Recruiting – February 2021 – NCT04431453
– Interventional – Phase 3 – Recruiting – March 2023 – NCT04315948
– Interventional – Phase 3 – Active, not recruiting – August 1, 2023 – NCT04401579
– Interventional – Phase 3 – Recruiting – November 1, 2023 – NCT04492475
Table 2. Summary of Remdesivir Findings (In Vitro) Reported in Selected Articles.
In vitro effectiveness of remdesivir against CoVs and COVID-19
Type of study Target Outcomes References
– In vitro (using Vero E6 cells) – SARS-CoV-2 – EC50 ¼ 0.77 mM against COVID-19 13
– In vitro – MERS and SARS – EC50 ¼ 0.07 & 0.069 mM against MERS and SARS-CoVs, respectively 14
– In vitro – RNA viruses – Potent inhibition of RNA viruses in cell based assays 8
– Opinion – COVID-19 – Appropriate potential biocontainment capability against COVID-19 15
– In silico – SARS-CoV-2 – Suggested as a potent drug against COVID-19 9
Abbreviations: CoVs (coronaviruses), COVID-19 (2019 coronavirus disease), SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), EC50 (half
maximal effective concentration), MERS (Middle East respiratory syndrome), SARS (severe acute respiratory syndrome), RNA (ribonucleic acid).
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Institute of Allergy and Infectious Diseases’ phase 3 trial. The
approval references the United States’ Emergency Use Author-
ization of the drug to treat severe cases of COVID-19.22
Furthermore, Gilead signed a licensing deal recently with
3 Indian companies to manufacture remdesivir.23
However, a recent randomized, double-blind, placebo-
controlled, multicenter trial published by Wang Y., et al., reported
that in this study of adult patients admitted to the hospital for
severe COVID-19 (who have pneumonia confirmed by chest ima-
ging, had SpO2 of 94% or lower on room air or a ratio of arterial
oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2)
of 300 mm Hg or less, or lung infiltrates >50%), remdesivir was
not related with statistically significant clinical aids. The patients
were admitted to hospital with an interval from symptom onset to
enrolment of 12 days or less. In this study, 158 out of 237 patients
received I.V remdesivir (200 mg on day 1 followed by 100 mg on
days 2-10 in single daily infusions) and observed that remdesivir
use was not associated with a difference in time to clinical
improvement (i.e., decrease in invasive mechanical ventilation,
length of oxygen support, hospital length of stay and, days from
randomization to discharge, increase in days from randomization
to death and a decline of one category, instead of 2 on 6-category
scale as discussed by Wang Y., et al.), mortality and viral clearance
in patients with severe COVID-19 in comparison with placebo.
Clinical improvement rates in remdesivir group were 3%, 27%
and, 65% as compared to placebo group of 3%, 23% and, 58% on
day 7, 14 and, 28 respectively. 66% of 155 remdesivir recipients
exhibited adverse events versus 64% of 78 placebo recipients. The
most common adverse events in the remdesivir group were con-
stipation (14%), hypoalbuminemia (13%), hypokalemia (12%),
anemia (12%), thrombocytopenia (10%), and increased total bilir-
ubin (10%). Weaknesses of this study were deficient power to
identify expected differences in clinical outcomes, the commence-
ment of treatment quite late in COVID-19, and the lack of data on
infectious virus recovery or on probable emergence of reduced
susceptibility to remdesivir. Although, this trial did not achieve
the programed sample size due to the outbreak of COVID-19 was
taken under control in China.19 However, the numerical decline in
time to clinical improvement in those treated earlier needs verifi-
cation in larger studies.
Furthermore, another double-blind, randomized, placebo-
controlled trial of I.V remdesivir in adults hospitalized with
COVID-19 concluded that remdesivir was superior to placebo
in shortening the time to recovery (defined as the first day, during
the 28 days after enrollment, on which a patient satisfied cate-
gories 1, 2, or 3 on the eight-category ordinal scale discussed by
Beigel JH., et al.).20 In this study, 538 patients were assigned to
remdesivir treatment and 521 to placebo. 88.7% of patients had
the severe disease (hospitalized COVID-19 cases with evidence
of lower respiratory tract infection) at enrollment. The median
number of days between symptom onset and randomization was
9. The results indicated that remdesivir-treated patients had a
median recovery time of 11 days versus 15 days in placebo group.
21.1% of patients experienced serious adverse effects who
received remdesivir while this percentage was 27% in placebo
group. The most common adverse events in the remdesivir group
were anemia (7.9%), acute kidney injury (7.4%), pyrexia (5.0%),
hyperglycemia (4.1%), and increased aminotransferase levels
(4.1%). Moreover, the estimates of mortality by 14 days were
7.1% with remdesivir and 11.9% with placebo.20 Though, these
findings favors the use of remdesivir for hospitalized COVID-19
patients and who require supplemental oxygen therapy. However,
given a high incidence of adverse events and mortality in spite of
the use of remdesivir, it is obvious that antiviral drug alone for
treating COVID-19 is not likely to be sufficient.
Therefore, for the enhanced safety of patients with
COVID-19, further clinical trials and large randomized con-
trolled studies are needed4 to validate the effective role, safety
profile, and adverse events of remdesivir along with other
therapeutic approaches and future strategies. However, any
approvals for the usage of a new drug, certainly, needs addi-
tional clinical testing, followed by the approval of widespread
Table 3. Summary of Remdesivir Findings (In Vivo) Reported in Selected Articles.
In vivo effectiveness of remdesivir against CoVs and COVID-19
Type of study Outcomes References
– Non-human primate study (rhesus macaque
model)
– Strong inhibition of MERS-CoV replication in respiratory tissues 16
– Case report – Patient recovered 17
– Compassionate-use study (Cohort study) – 68% improvement in clinical conditions of patients 18
– Randomized, double-blind, placebo controlled,
multicenter trial (Prospective study)
– No significant clinical benefits observed in remdesivir recipients
– Clinical improvement rates in remdesivir group (3%, 27% and 65%) vs placebo
group (3%, 23% and 58%) on day 7, 14 and 28, respectively
– 66% remdesivir recipients exhibited adverse events
19
– Double-blind, randomized, placebo-controlled
trial (Prospective study)
– Remdesivir was superior to placebo in shortening the time to recovery
– Remdesivir [median recovery time 11 days (95% CI: 9 to 12 days), 21.1% adverse
events, 7.1% mortality estimates[
– Placebo [median recovery time 15 days (95% CI: 13 to 19 days), 27% adverse
events,11.9% mortality estimates]
20
Abbreviations: CoVs (coronaviruses), COVID-19 (2019 coronavirus disease), MERS-CoV (middle east respiratory syndrome coronavirus), 95% CI (95%
confidence interval).
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use by the pertinent regulatory authority for medical treatment.
To accomplish this, the concentration of the studies may impor-
tant to be on the direct human clinical approaches in maximum
quantity along with in vitro studies to approve the efficacy as
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